257. Baruchel, A.; Abrahamsson, J.; Bertrand, Y.; Gonzalez, O.; Nysom, K.; Quinones, W.; Rizzari, C.; Buechner, J.; Cesaro, S.; Duarte, J.; et al. Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis. *Blood* **2021**, *138*, 516. [CrossRef]

258. Hashmi, H.; Husnain, M.; Khan, A.; Usmani, S.Z. CD38-Directed Therapies for Management of Multiple Myeloma. *Immunotargets Ther.* **2021**, *10*, 201–211. [CrossRef]

259. Abramson, H.N. *Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma*; IntechOpen: London, UK, 2020; pp. 1–20.

260. Raab, M.S.; Engelhardt, M.; Blank, A.; Goldschmidt, H.; Agis, H.; Blau, I.W.; Einsele, H.; Ferstl, B.; Schub, N.; Röllig, C.; et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: A first-in-human, multicentre, phase 1-2a trial. *Lancet Haematol.* **2020**, *7*, e381–e394. [CrossRef]

261. Krishnan, A.Y.; Patel, K.K.; Hari, P.; Jagannath, S.; Niesvizky, R.; Silbermann, R.W.; Berg, D.T.; Li, Q.; Allikmets, K.; Stockerl-Goldstein, K. A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM): Preliminary results. *J. Clin. Oncol.* **2020**, *38*, 8539. [CrossRef]

262. Zuch de Zafra, C.L.; Fajardo, F.; Zhong, W.; Bernett, M.J.; Muchhal, U.S.; Moore, G.L.; Stevens, J.; Case, R.; Pearson, J.T.; Liu, S.; et al. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. *Clin. Cancer Res.* **2019**, *25*, 3921–3933. [CrossRef] [PubMed]

263. Doucey, M.A.; Estoppey, C.; Stutz, C.; Croset, A.; Laurendon, A.; Monney, T.; Pluess, M.; Ries-Fecourt, C.; Macoin, J.; Turrini, R.; et al. ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma. *J. Clin. Oncol.* **2021**, *39*, 8044. [CrossRef]

264. Guo, Y.; Feng, K.; Tong, C.; Jia, H.; Liu, Y.; Wang, Y.; Ti, D.; Yang, Q.; Wu, Z.; Han, W. Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. *Cell. Mol. Immunol.* **2020**, *17*, 430–432. [CrossRef]

265. Duggal, R.; Santara, S.S.; Gordon, M.; Kilgallon, A.; Hermanson, D.; Childs, R.W.; O'Dwyer, M.E. Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma. *Blood* **2021**, *138*, 4793. [CrossRef]

266. Stikvoort, A.; van der Schans, J.; Sarkar, S.; Poels, R.; Ruiter, R.; Naik, J.; Yuan, H.; de Bruijn, J.D.; van de Donk, N.W.; Zweegman, S.; et al. CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma. *HemaSphere* **2021**, *5*, e596. [CrossRef]

267. Cho, S.F.; Anderson, K.C.; Tai, Y.T. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. *Front. Immunol.* **2018**, *9*, 1821. [CrossRef]

268. Zhou, X.; Mulazzani, M.; von Mücke-Heim, I.A.; Langer, S.; Zhang, W.; Ishikawa-Ankerhold, H.; Dreyling, M.; Straube, A.; von Baumgarten, L. The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma. *Front. Oncol.* **2020**, *10*, 682. [CrossRef]

269. Sanchez, L.; Dardac, A.; Madduri, D.; Richard, S.; Richter, J. B-cell maturation antigen (BCMA) in multiple myeloma: The new frontier of targeted therapies. *Ther. Adv. Hematol.* **2021**, *12*, 2040620721989585. [CrossRef]

270. Lancman, G.; Richter, J.; Chari, A. Bispecifics, trispecifics, and other novel immune treatments in myeloma. *Hematol. Am. Soc. Hematol. Educ. Program* **2020**, *2020*, 264–271. [CrossRef]

271. Strassl, I.; Schreder, M.; Steiner, N.; Rudzki, J.; Agis, H.; Künz, T.; Müser, N.; Willenbacher, W.; Petzer, A.; Neumeister, P.; et al. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. *Cancers* **2021**, *13*, 4701. [CrossRef]

272. Sheikh, S.; Lebel, E.; Trudel, S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. *Future Oncol.* **2020**, *16*, 2783–2798. [CrossRef] [PubMed]

273. Trudel, S.; Nooka, A.; Fecteau, D.; Talekar, M.; Jewell, R.C.; Williams, D.; Evans, J.; Opalinska, J. DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). *Ann. Oncol.* **2019**, *30*, v447. [CrossRef]

274. Xing, L.; Lin, L.; Yu, T.; Li, Y.; Cho, S.F.; Liu, J.; Wen, K.; Hsieh, P.A.; Kinneer, K.; Munshi, N.; et al. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. *Leukemia* **2020**, *34*, 2150–2162. [CrossRef]

275. Kumar, S.; Migkou, M.; Bhutani, M.; Spencer, A.; Ailawadhi, S.; Kalff, A.; Walcott, F.; Pore, N.; Gibson, D.; Wang, F.; et al. Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. *Blood* **2020**, *136*, 26–27. [CrossRef]

276. Trudel, S.; Lendvai, N.; Popat, R.; Voorhees, P.M.; Reeves, B.; Libby, E.N.; Richardson, P.G.; Hoos, A.; Gupta, I.; Bragulat, V.; et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. *Blood Cancer J.* **2019**, *9*, 37. [CrossRef]

277. Lee, H.C.; Raje, N.S.; Landgren, O.; Upreti, V.V.; Wang, J.; Avilion, A.A.; Hu, X.; Rasmussen, E.; Ngarmchamnanrith, G.; Fujii, H.; et al. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. *Leukemia* **2021**, *35*, 255–258. [CrossRef]
278. Usmani, S.Z.; Garfall, A.L.; van de Donk, N.; Nahi, H.; San-Miguel, J.F.; Oriol, A.; Rosinol, L.; Chari, A.; Bhutani, M.; Karlin, L.; et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. *Lancet* **2021**, *398*, 665–674. [CrossRef]

279. Munshi, N.C.; Anderson, L.D., Jr.; Shah, N.; Madduri, D.; Berdeja, J.; Lonial, S.; Raje, N.; Lin, Y.; Siegel, D.; Oriol, A.; et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N. Engl. J. Med.* **2021**, *384*, 705–716. [CrossRef]

280. Costa, L.J.; Lin, Y.; Cornell, R.F.; Martin, T.; Chhabra, S.; Usmani, S.Z.; Jagannath, S.; Callander, N.S.; Berdeja, J.G.; Kang, Y.; et al. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. *Clin. Lymphoma Myeloma Leuk.* **2022**, *22*, 326–335. [CrossRef] [PubMed]

281. Tang, Y.; Yin, H.; Zhao, X.; Jin, D.; Liang, Y.; Xiong, T.; Li, L.; Tang, W.; Zhang, J.; Liu, M.; et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. *J. Exp. Clin. Cancer Res.* **2022**, *41*, 2. [CrossRef] [PubMed]

282. Ng, Y.Y.; Du, Z.; Zhang, X.; Chng, W.J.; Wang, S. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. *Cancer Gene Ther.* **2022**, *29*, 475–483. [CrossRef]

283. Ding, W.; LaPlant, B.R.; Call, T.G.; Parikh, S.A.; Leis, J.F.; He, R.; Shanafelt, T.D.; Sinha, S.; Le-Rademacher, J.; Feldman, A.L.; et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood* **2017**, *129*, 3419–3427. [CrossRef]

284. Sandhu, K.S.; Huynh-Tran, Q.; Cooper, E.E.; Palmer, J.; Tsai, N.C.; Thomas, S.; Robbins, M.; Aribi, A.; Salhotra, A.; Mei, M.; et al. ALL-440: Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). *Clin. Lymphoma Leukemia* **2021**, *21*, 276. [CrossRef]

285. Carlo-Stella, C.; Zinzani, P.L.L.; Sureda, A.; Araújo, L.F.; Casasnovas, O.; Carpio, C.; Yeh, S.P.; Bouabdallah, K.; Cartron, G.; Kim, W.S.; et al. A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma. *Blood* **2021**, *138*, 4362. [CrossRef]

286. Jacobson, C.S.J. End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. *Blood* **2018**, *132*, 4192. [CrossRef]

287. Treon, S.P.; Meid, K.; Hunter, Z.R.; Flynn, C.A.; Sarosiek, S.R.; Leventoff, C.R.; White, T.P.; Cao, Y.; Roccaro, A.M.; Sacco, A.; et al. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. *Blood* **2021**, *138*, 1535–1539. [CrossRef]

288. Schjesvold, F.; Robak, P.; Pour, L.; Aschan, J.; Sonneveld, P. OCEAN: A randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. *Future Oncol.* **2020**, *16*, 631–641. [CrossRef] [PubMed]

289. Kolstad, A.; Illidge, T.; Bolstad, N.; Spetalen, S.; Madsbu, U.; Stokke, C.; Blakkisrud, J.; Løndalen, A.; O'Rourke, N.; Beasley, M.; et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. *Blood Adv.* **2020**, *4*, 4091–4101. [CrossRef] [PubMed]

290. Wang, C.M.; Wu, Z.Q.; Wang, Y.; Guo, Y.L.; Dai, H.R.; Wang, X.H.; Li, X.; Zhang, Y.J.; Zhang, W.Y.; Chen, M.X.; et al. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. *Clin. Cancer Res.* **2017**, *23*, 1156–1166. [CrossRef]

291. Ramos, C.A.; Ballard, B.; Zhang, H.; Dakhova, O.; Gee, A.P.; Mei, Z.; Bilgi, M.; Wu, M.F.; Liu, H.; Grilley, B.; et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. *J. Clin. Investig.* **2017**, *127*, 3462–3471. [CrossRef]

292. Advani, R.H.; Flinn, I.; Popplewell, L.; Forero-Torres, A.; Bartlett, N.L.; Ghosh, N.; Kline, J.P.; Tran, T.; Lynn, J.; Chen, J.Y.; et al. Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. *J. Clin. Oncol.* **2018**, *36*, 7504. [CrossRef]

293. Chauchet, X.; Cons, L.; Chatel, L.; Daubeuf, B.; Didelot, G.; Moine, V.; Chollet, D.; Malinge, P.; Pontini, G.; Masternak, K.; et al. CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. *Exp. Hematol. Oncol.* **2022**, *11*, 26. [CrossRef]

294. Krishnan, A.Y.; Shah, N.; Spira, A.I.; Kaufman, J.L.; Niesvizky, R.; Shah, N.N.; Burke, J.M.; Popplewell, L.; Martin, T.G.; Cheung, J.; et al. A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies. *J. Clin. Oncol.* **2018**, *36*, 7586. [CrossRef]

295. Cohen, A.D.; Harrison, S.J.; Krishnan, A.; Fonseca, R.; Forsberg, P.A.; Spencer, A.; Berdeja, J.G.; Laubach, J.P.; Li, M.; Choeurng, V.; et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma. *Blood* **2020**, *136*, 42–43. [CrossRef]

296. Berdeja, J.G.; Krishnan, A.Y.; Oriol, A.; van de Donk, N.W.; Rodríguez-Otero, P.; Askari, E.; Mateos, M.V.; Minnema, M.C.; Costa, L.J.; Verona, R.; et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). *J. Clin. Oncol.* **2021**, *39*, 8008. [CrossRef]

297. Cui, B.; Ghia, E.M.; Chen, L.; Rassenti, L.Z.; DeBoever, C.; Widhopf, G.F., 2nd; Yu, J.; Neuberg, D.S.; Wierda, W.G.; Rai, K.R.; et al. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. *Blood* **2016**, *128*, 2931–2940. [CrossRef]
298. Fukuda, T.; Chen, L.; Endo, T.; Tang, L.; Lu, D.; Castro, J.E.; Widhopf, G.F., 2nd; Rassenti, L.Z.; Cantwell, M.J.; Prussak, C.E.; et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 3047–3052. [CrossRef] [PubMed]

299. Yu, J.; Chen, L.; Cui, B.; Widhopf, G.F., 2nd; Shen, Z.; Wu, R.; Zhang, L.; Zhang, S.; Briggs, S.P.; Kipps, T.J. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. *J. Clin. Investig.* **2016**, *126*, 585–598. [CrossRef]

300. Ghia, E.M.; Rassenti, L.Z.; Choi, M.Y.; Quijada-Álamo, M.; Chu, E.; Widhopf, G.F., 2nd; Kipps, T.J. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. *Leukemia* **2022**, *36*, 1609–1618. [CrossRef]

301. Choi, M.Y.; Widhopf, G.F., 2nd; Ghia, E.M.; Kidwell, R.L.; Hasan, M.K.; Yu, J.; Rassenti, L.Z.; Chen, L.; Chen, Y.; Pittman, E.; et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. *Cell Stem Cell* **2018**, *22*, 951–959.e3. [CrossRef]

302. Beenen, A.C.; Sauerer, T.; Schaft, N.; Dörrie, J. Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. *Int. J. Mol. Sci.* **2022**, *23*, 8599. [CrossRef] [PubMed]

303. Zhao, X.; Bao, Y.; Meng, B.; Xu, Z.; Li, S.; Wang, X.; Hou, R.; Ma, W.; Liu, D.; Zheng, J.; et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. *Front. Immunol.* **2022**, *13*, 920021. [CrossRef] [PubMed]

304. Wang, Y.; Zhang, H.; Liu, C.; Wang, Z.; Wu, W.; Zhang, N.; Zhang, L.; Hu, J.; Luo, P.; Zhang, J.; et al. Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts. *J. Hematol. Oncol.* **2022**, *15*, 111. [CrossRef] [PubMed]

305. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N. Engl. J. Med.* **2012**, *366*, 2455–2465. [CrossRef]

306. Boyiadzis, M.M.; Kirkwood, J.M.; Marshall, J.L.; Pritchard, C.C.; Azad, N.S.; Gulley, J.L. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. *J. Immunother. Cancer* **2018**, *6*, 35. [CrossRef] [PubMed]

307. Lesokhin, A.M.; Ansell, S.M.; Armand, P.; Scott, E.C.; Halwani, A.; Gutierrez, M.; Millenson, M.M.; Cohen, A.D.; Schuster, S.J.; Lebovic, D.; et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. *J. Clin. Oncol.* **2016**, *34*, 2698–2704. [CrossRef] [PubMed]

308. Armand, P.; Lesokhin, A.; Borrello, I.; Timmerman, J.; Gutierrez, M.; Zhu, L.; Popa McKiver, M.; Ansell, S.M. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. *Leukemia* **2021**, *35*, 777–786. [CrossRef] [PubMed]

309. Bertamini, L.; Gay, F. Checkpoint inhibitors and myeloma: Promises, deadlocks and new directions. *Ann. Transl. Med.* **2020**, *8*, 777. [CrossRef]

310. Casulo, C.; Santoro, A.; Ando, K.; Le Gouill, S.; Ruan, J.; Radford, J.; Arcaini, L.; Pinto, A.; Bouabdallah, R.; Izutsu, K.; et al. Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial. *Blood* **2019**, *134*, 5320. [CrossRef]

311. Ribrag, V.; Lee, S.T.; Rizzieri, D.; Dyer, M.J.S.; Fayad, L.; Kurzrock, R.; Andritsos, L.; Bouabdallah, R.; Hayat, A.; Bacon, L.; et al. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination with Tremelimumab or Danvatirsen in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clin. Lymphoma Myeloma Leuk.* **2021**, *21*, 309–317.e3. [CrossRef]

312. Hirayama, A.V.; Gauthier, J.; Hay, K.A.; Sheih, A.; Cherian, S.; Chen, X.; Pender, B.S.; Hawkins, R.M.; Vakil, A.; Steinmetz, R.N.; et al. Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. *Blood* **2018**, *132*, 1680. [CrossRef]

313. Kaiser, L.M.; Hunter, Z.R.; Treon, S.P.; Buske, C. CXCR4 in Waldenström's Macroglobulinemia: Chances and challenges. *Leukemia* **2021**, *35*, 333–345. [CrossRef] [PubMed]

314. Kashyap, M.K.; Kumar, D.; Jones, H.; Amaya-Chanaga, C.I.; Choi, M.Y.; Melo-Cardenas, J.; Ale-Ali, A.; Kuhne, M.R.; Sabbatini, P.; Cohen, L.J.; et al. Ulocuplumab (BMS-936564/MDX1338): A fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. *Oncotarget* **2016**, *7*, 2809–2822. [CrossRef]

315. Roccaro, A.M.; Sacco, A.; Jimenez, C.; Maiso, P.; Moschetta, M.; Mishima, Y.; Aljawai, Y.; Sahin, I.; Kuhne, M.; Cardarelli, P.; et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood* **2014**, *123*, 4120–4131. [CrossRef]

316. Ghobrial, I.M.; Liu, C.J.; Redd, R.A.; Perez, R.P.; Baz, R.; Zavidij, O.; Sklavenitis-Pistofidis, R.; Richardson, P.G.; Anderson, K.C.; Laubach, J.; et al. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. *Clin. Cancer Res.* **2020**, *26*, 344–353. [CrossRef] [PubMed]

317. Rasche, L.; Wäsch, R.; Munder, M.; Goldschmidt, H.; Raab, M.S. Novel immunotherapies in multiple myeloma—Chances and challenges. *Haematologica* **2021**, *106*, 2555–2565. [CrossRef] [PubMed]

318. Gormley, N.J.; Ko, C.W.; Deisseroth, A.; Nie, L.; Kaminskas, E.; Kormanik, N.; Goldberg, K.B.; Farrell, A.T.; Pazdur, R. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. *Clin. Cancer Res.* **2017**, *23*, 6759–6763. [CrossRef]

319. Bauvois, B. Transmembrane proteases in focus: Diversity and redundancy? *J. Leukoc. Biol.* **2001**, *70*, 11–17. [CrossRef]
320. Verhulst, E.; Garnier, D.; De Meester, I.; Bauvois, B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? *Cancers* **2022**, *14*, 624. [CrossRef] [PubMed]

321. Schliemann, C.; Gerwing, M.; Heinzow, H.; Harrach, S.; Schwöppe, C.; Wildgruber, M.; Hansmeier, A.A.; Angenendt, L.; Berdel, A.F.; Stalmann, U.; et al. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. *Cancers* **2020**, *12*, 1488. [CrossRef] [PubMed]

322. Berglund, Å.; Ullén, A.; Lisyanskaya, A.; Orlov, S.; Hagberg, H.; Tholander, B.; Lewensohn, R.; Nygren, P.; Spira, J.; Harmenberg, J.; et al. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. *Investig. New Drugs* **2015**, *33*, 1232–1241. [CrossRef]

323. Richardson, P.G.; Oriol, A.; Larocca, A.; Bladé, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Nadeem, O.; Hiemenz, J.W.; Hassoun, H.; et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. *J. Clin. Oncol.* **2021**, *39*, 757–767. [CrossRef] [PubMed]

324. Kudo, K.; Imai, C.; Lorenzini, P.; Kamiya, T.; Kono, K.; Davidoff, A.M.; Chng, W.J.; Campana, D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. *Cancer Res.* **2014**, *74*, 93–103. [CrossRef] [PubMed]

325. Munoz, J.; Jaglowski, S.; McKinney, M.S.; Isufi, I.; Stiff, P.J.; Sachs, J.; Ranger, A.; Harris, P.; Payumo, F.; Akard, L.P. A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma. *Blood* **2019**, *134*, 244. [CrossRef]

326. Merli, M.; Ferrario, A.; Maffioli, M.; Olivares, C.; Stasia, A.; Arcaini, L.; Passamonti, F. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. *Expert Rev. Hematol.* **2016**, *9*, 767–780. [CrossRef]

327. Grover, N.S.; Savoldo, B. Challenges of driving CD30-directed CAR-T cells to the clinic. *BMC Cancer* **2019**, *19*, 203. [CrossRef]

328. Rodrigues-Fernandes, C.I.; Abreu, L.G.; Radhakrishnan, R.; Perez, D.; Amaral-Silva, G.K.; Gondak, R.O.; Rahimi, S.; Brennan, P.A.; Fonseca, F.P.; Vargas, P.A. Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis. *J. Oral Pathol. Med.* **2021**, *50*, 587–593. [CrossRef] [PubMed]

329. Atrash, S.; Moyo, T.K. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. *OncoTargets Ther.* **2021**, *14*, 2185–2201. [CrossRef] [PubMed]

330. Ho, C.; Ruella, M.; Levine, B.L.; Svoboda, J. Adoptive T-cell therapy for Hodgkin lymphoma. *Blood Adv.* **2021**, *5*, 4291–4302. [CrossRef]

331. Witkowska, M.; Smolewski, P.; Robak, T. Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. *Expert Opin. Investig. Drugs* **2018**, *27*, 171–177. [CrossRef] [PubMed]

332. Payandeh, Z.; Noori, E.; Khalesi, B.; Mard-Soltani, M.; Abdolalizadeh, J.; Khalili, S. Anti-CD37 targeted immunotherapy of B-Cell malignancies. *Biotechnol. Lett.* **2018**, *40*, 1459–1466. [CrossRef] [PubMed]

333. Bobrowicz, M.; Kubacz, M.; Slusarczyk, A.; Winiarska, M. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies. *Int. J. Mol. Sci.* **2020**, *21*, 9531. [CrossRef] [PubMed]

334. Danilov, A.V.; Spurgeon, S.E.; Siddiqi, T.; Quinson, A.M.; Maier, D.; Smith, D.; Brown, J.R. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. *Investig. New Drugs* **2021**, *39*, 1099–1105. [CrossRef] [PubMed]

335. Yin, Z.; Zhang, Y.; Wang, X. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. *Biomark Res.* **2021**, *9*, 58. [CrossRef]

336. Kroschinsky, F.; Middeke, J.M.; Janz, M.; Lenz, G.; Witzens-Harig, M.; Bouabdallah, R.; La Rosée, P.; Viardot, A.; Salles, G.; Kim, S.J.; et al. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. *Investig. New Drugs* **2020**, *38*, 1472–1482. [CrossRef] [PubMed]

337. Stathis, A.; Flinn, I.W.; Madan, S.; Maddocks, K.; Freedman, A.; Weitman, S.; Zucca, E.; Munteanu, M.C.; Lia Palomba, M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study. *Investig. New Drugs* **2018**, *36*, 869–876. [CrossRef] [PubMed]

338. Levy, M.Y.; Jagadeesh, D.; Grudeva-Popova, Z.; Trněný, M.; Jurczak, W.; Pylypenko, H.; André, M.; Nasta, S.D.; Rechavi-Robinson, D.; Toffanin, S.; et al. Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas-a Phase 2 Study. *Blood* **2021**, *138*, 526. [CrossRef]

339. Sawas, A.; Savage, K.J.; Perez, R.P.; Advani, R.H.; Melhem-Bertrandt, A.; Lackey, J.; Trave, F.; Anand, B.; Huang, Y.; Vincent, M.; et al. A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. *J. Clin. Oncol.* **2016**, *34*, 7549. [CrossRef]

340. Elvington, M.; Liszewski, M.K.; Atkinson, J.P. CD46 and Oncologic Interactions: Friendly Fire against Cancer. *Antibodies* **2020**, *9*, 59. [CrossRef] [PubMed]

341. Wong, S.; Imus, P.; Mark, T.; Kaufman, J.; Imus, A.; Zonder, J.A.; Walker, Z.; Sherbenou, D.; Schroeder, M.; Abbey, J.; et al. P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma. *Clin. Lymphoma Myeloma Leuk.* **2021**, *21*, 164. [CrossRef]

342. Sick, E.; Jeanne, A.; Schneider, C.; Dedieu, S.; Takeda, K.; Martiny, L. CD47 update: A multifaceted actor in the tumour microenvironment of potential therapeutic interest. *Br. J. Pharmacol.* **2012**, *167*, 1415–1430. [CrossRef] [PubMed]

343. Maute, R.; Xu, J.; Weissman, I.L. CD47-SIRPα-targeted therapeutics: Status and prospects. *Immuno. Oncol. Technol.* **2022**, *13*, 100070. [CrossRef]
344. Jiang, Z.; Sun, H.; Yu, J.; Tian, W.; Song, Y. Targeting CD47 for cancer immunotherapy. *J. Hematol. Oncol.* **2021**, *14*, 180. [CrossRef]

345. Saygin, C.; Carraway, H.E. Current and emerging strategies for management of myelodysplastic syndromes. *Blood Rev.* **2021**, *48*, 100791. [CrossRef]

346. Gilead. Safety Concerns Prompt Pause of Magrolimab Trials. *Cancer Discov.* **2022**, *12*, 877–878. [CrossRef] [PubMed]

347. Lambert, J.M.; O'Leary, J.; Whiteman, K.R.; Goldmacher, V.S. Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine. In *Antibody-Drug Conjugates and Immunotoxins*; Springer: New York, NY, USA, 2012; pp. 273–293.

348. Ailawadhi, S.; Kelly, K.R.; Vescio, R.A.; Jagannath, S.; Wolf, J.; Gharibo, M.; Sher, T.; Bojanini, L.; Kirby, M.; Chanan-Khan, A. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. *Clin. Lymphoma Myeloma Leuk.* **2019**, *19*, 29–34. [CrossRef]

349. Gil-Yarom, N.; Radomir, L.; Sever, L.; Kramer, M.P.; Lewinsky, H.; Bornstein, C.; Blecher-Gonen, R.; Barnett-Itzhaki, Z.; Mirkin, V.; Friedlander, G.; et al. CD74 is a novel transcription regulator. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 562–567. [CrossRef] [PubMed]

350. Stein, R.; Mattes, M.J.; Cardillo, T.M.; Hansen, H.J.; Chang, C.H.; Burton, J.; Govindan, S.; Goldenberg, D.M. CD74: A new candidate target for the immunotherapy of B-cell neoplasms. *Clin. Cancer Res.* **2007**, *13*, 5556s–5563s. [CrossRef] [PubMed]

351. Kaufman, J.L.; Niesvizky, R.; Stadtmauer, E.A.; Chanan-Khan, A.; Siegel, D.; Horne, H.; Wegener, W.A.; Goldenberg, D.M. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. *Br. J. Haematol.* **2013**, *163*, 478–486. [CrossRef] [PubMed]

352. Abrahams, C.L.; Li, X.; Embry, M.; Yu, A.; Krimm, S.; Krueger, S.; Greenland, N.Y.; Wen, K.W.; Jones, C.; DeAlmeida, V.; et al. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. *Oncotarget* **2018**, *9*, 37700–37714. [CrossRef] [PubMed]

353. Sawalha, Y.; Maddocks, K. Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data. *Onco Targets Ther.* **2020**, *13*, 5123–5133. [CrossRef] [PubMed]

354. Arribas, J.; Esselens, C. ADAM17 as a therapeutic target in multiple diseases. *Curr. Pharm. Des.* **2009**, *15*, 2319–2335. [CrossRef]

355. Witters, L.; Scherle, P.; Friedman, S.; Fridman, J.; Caulder, E.; Newton, R.; Lipton, A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. *Cancer Res.* **2008**, *68*, 7083–7089. [CrossRef] [PubMed]

356. Bachanova, V.; Kolla, B.; Cao, Q.; Weisdorf, D.; Rashidi, A.; Warlick, E.; El Jurdi, N.; Wangen, R.; Arora, M.; Brunstein, C.; et al. ADAM17 Inhibitor INCB7839 With Rituximab As Consolidation After Autologous Hct For Diffuse Large B Cell Lymphoma: A Novel Relapse Prevention Strategy. In *Proceedings of the Virtual 46th Annual Meeting of the EBMT, Virtual, 29 August–1 September 2020*; p. 133. Available online: https://www.ebmt.org/46th-annual-meeting-ebmt (accessed on 6 November 2022).

357. Polson, A.G.; Zheng, B.; Elkins, K.; Chang, W.; Du, C.; Dowd, P.; Yen, L.; Tan, C.; Hongo, J.A.; Koeppen, H.; et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. *Int. Immunol.* **2006**, *18*, 1363–1373. [CrossRef]

358. Ise, T.; Nagata, S.; Kreitman, R.J.; Wilson, W.H.; Wayne, A.S.; Stetler-Stevenson, M.; Bishop, M.R.; Scheinberg, D.A.; Rassenti, L.; Kipps, T.J.; et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. *Leukemia* **2007**, *21*, 169–174. [CrossRef]

359. Smith, E.L.; Harrington, K.; Staehr, M.; Masakayan, R.; Jones, J.; Long, T.J.; Ng, K.Y.; Ghoddusi, M.; Purdon, T.J.; Wang, X.; et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci. Transl. Med.* **2019**, *11*, eaau7746. [CrossRef] [PubMed]

360. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70. [CrossRef] [PubMed]

361. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [CrossRef] [PubMed]

362. Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* **2016**, *23*, 27–47. [CrossRef]

363. Kirsch, B.J.; Chang, S.J.; Betenbaugh, M.J.; Le, A. Non-Hodgkin Lymphoma Metabolism. *Adv. Exp. Med. Biol.* **2021**, *1311*, 103–116.

364. Bhalla, K.; Jaber, S.; Nahid, M.N.; Underwood, K.; Beheshti, A.; Landon, A.; Bhandary, B.; Bastian, P.; Evens, A.M.; Haley, J.; et al. Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. *Sci. Rep.* **2018**, *8*, 744. [CrossRef] [PubMed]

365. Nakajima, K.; Kawashima, I.; Koshiisi, M.; Kumagai, T.; Suzuki, M.; Suzuki, J.; Mitsumori, T.; Kirito, K. Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma. *Exp. Hematol.* **2019**, *78*, 46–55.e3. [CrossRef]

366. Lu, J.; Böttcher, M.; Walther, T.; Mougiakakos, D.; Zenz, T.; Huber, W. Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity. *Haematologica* **2019**, *104*, 1830–1840. [CrossRef] [PubMed]

367. Adekola, K.U.; Dalva Aydemir, S.; Ma, S.; Zhou, Z.; Rosen, S.T.; Shanmugam, M. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. *Leuk. Lymphoma* **2015**, *56*, 450–459. [CrossRef]

368. Dalva-Aydemir, S.; Bajpai, R.; Martinez, M.; Adekola, K.U.; Kandela, I.; Wei, C.; Singhal, S.; Koblinski, J.E.; Raje, N.S.; Rosen, S.T.; et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. *Clin. Cancer Res.* **2015**, *21*, 1161–1171. [CrossRef] [PubMed]

369. Zhao, H.; Swanson, K.D.; Zheng, B. Therapeutic Repurposing of Biguanides in Cancer. *Trends Cancer* **2021**, *7*, 714–730. [CrossRef]

370. Hartmann, S.; Agostinelli, C.; Diener, J.; Döring, C.; Fanti, S.; Zinzani, P.L.; Gallamini, A.; Bergmann, L.; Pileri, S.; Hansmann, M.L. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. *BMC Cancer* **2012**, *12*, 586. [CrossRef]
371. Afonso, J.; Pinto, T.; Simões-Sousa, S.; Schmitt, F.; Longatto-Filho, A.; Pinheiro, C.; Marques, H.; Baltazar, F. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma-MCT1 as potential target in diffuse large B cell lymphoma. *Cell Oncol. (Dordr.)* **2019**, *42*, 303–318. [CrossRef] [PubMed]

372. Noble, R.A.; Bell, N.; Blair, H.; Sikka, A.; Thomas, H.; Phillips, N.; Nakjang, S.; Miwa, S.; Crossland, R.; Rand, V.; et al. Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. *Haematologica* **2017**, *102*, 1247–1257. [CrossRef]

373. Halford, S.E.; Walter, H.; McKay, P.; Townsend, W.; Linton, K.; Heinzmann, K.; Dragoni, I.; Brotherton, L.; Veal, G.; Siskos, A.; et al. Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). *J. Clin. Oncol.* **2021**, *39*, 3115. [CrossRef]

374. Xiao, G.; Chan, L.N.; Klemm, L.; Braas, D.; Chen, Z.; Geng, H.; Zhang, Q.C.; Aghajanirefah, A.; Cosgun, K.N.; Sadras, T.; et al. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. *Cell* **2018**, *173*, 470–484.e18. [CrossRef] [PubMed]

375. Zhang, L.; Yao, Y.; Zhang, S.; Liu, Y.; Guo, H.; Ahmed, M.; Bell, T.; Zhang, H.; Han, G.; Lorence, E.; et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. *Sci. Transl. Med.* **2019**, *11*, eaau1167. [CrossRef]

376. Zhan, X.; Yu, W.; Franqui-Machin, R.; Bates, M.L.; Nadiminti, K.; Cao, H.; Amendt, B.A.; Jethava, Y.; Frech, I.; Zhan, F.; et al. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. *Oncotarget* **2017**, *8*, 111213–111224. [CrossRef] [PubMed]

377. Galicia-Vázquez, G.; Aloyz, R. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? *Crit. Rev Oncol. Hematol.* **2019**, *134*, 65–70. [CrossRef] [PubMed]

378. Nie, Y.; Yun, X.; Zhang, Y.; Wang, X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. *Exp. Hematol. Oncol.* **2022**, *11*, 39. [CrossRef] [PubMed]

379. Jitschin, R.; Hofmann, A.D.; Bruns, H.; Gießl, A.; Bricks, J.; Berger, J.; Saul, D.; Eckart, M.J.; Mackensen, A.; Mougiakakos, D. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. *Blood* **2014**, *123*, 2663–2672. [CrossRef]

380. Ecker, V.; Stumpf, M.; Brandmeier, L.; Neumayer, T.; Pfeuffer, L.; Engleitner, T.; Ringshausen, I.; Nelson, N.; Jücker, M.; Wanninger, S.; et al. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. *Nat. Commun.* **2021**, *12*, 3526. [CrossRef]

381. Noble, R.A.; Thomas, H.; Zhao, Y.; Herendi, L.; Howarth, R.; Dragoni, I.; Keun, H.C.; Vellano, C.P.; Marszalek, J.R.; Wedge, S.R. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. *Br. J. Cancer* **2022**, *127*, 937–947. [CrossRef]

382. Zachar, Z.; Marecek, J.; Maturo, C.; Gupta, S.; Stuart, S.D.; Howell, K.; Schauble, A.; Lem, J.; Piramzadian, A.; Karnik, S.; et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. *J. Mol. Med.* **2011**, *89*, 1137–1148. [CrossRef]

383. Stuart, S.D.; Schauble, A.; Gupta, S.; Kennedy, A.D.; Keppler, B.R.; Bingham, P.M.; Zachar, Z. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. *Cancer Metab.* **2014**, *2*, 4. [CrossRef]

384. Ambrosio, M.R.; Piccaluga, P.P.; Ponzoni, M.; Rocca, B.J.; Malagnino, V.; Onorati, M.; De Falco, G.; Calbi, V.; Ogwang, M.; Naresh, K.N.; et al. The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: Adipophilin. *PLoS ONE* **2012**, *7*, e44315. [CrossRef] [PubMed]

385. Heintel, D.; Kienle, D.; Shehata, M.; Kröber, A.; Kroemer, E.; Schwarzinger, I.; Mitteregger, D.; Le, T.; Gleiss, A.; Mannhalter, C.; et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. *Leukemia* **2005**, *19*, 1216–1223. [CrossRef] [PubMed]

386. Rozovski, U.; Grgurevic, S.; Bueso-Ramos, C.; Harris, D.M.; Li, P.; Liu, Z.; Wu, J.Y.; Jain, P.; Wierda, W.; Burger, J.; et al. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. *Mol. Cancer Res.* **2015**, *13*, 944–953. [CrossRef] [PubMed]

387. Pallasch, C.P.; Schwamb, J.; Königs, S.; Schulz, A.; Debey, S.; Kofler, D.; Schultze, J.L.; Hallek, M.; Ultsch, A.; Wendtner, C.M. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. *Leukemia* **2008**, *22*, 585–592. [CrossRef]

388. Gelebart, P.; Zak, Z.; Anand, M.; Belch, A.; Lai, R. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. *PLoS ONE* **2012**, *7*, e33738. [CrossRef]

389. Uddin, S.; Hussain, A.R.; Ahmed, M.; Abubaker, J.; Al-Sanea, N.; Abduljabbar, A.; Ashari, L.H.; Alhomoud, S.; Al-Dayel, F.; Bavi, P.; et al. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. *Am. J. Gastroenterol.* **2009**, *104*, 1790–1801. [CrossRef]

390. Rozovski, U.; Harris, D.M.; Li, P.; Liu, Z.; Jain, P.; Ferrajoli, A.; Burger, J.; Thompson, P.; Jain, N.; Wierda, W.; et al. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. *Oncotarget* **2018**, *9*, 21268–21280. [CrossRef]

391. Liu, P.P.; Liu, J.; Jiang, W.Q.; Carew, J.S.; Ogasawara, M.A.; Pelicano, H.; Croce, C.M.; Estrov, Z.; Xu, R.H.; Keating, M.J.; et al. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. *Oncogene* **2016**, *35*, 5663–5673. [CrossRef]
392. Bolzoni, M.; Chiu, M.; Accardi, F.; Vescovini, R.; Airoldi, I.; Storti, P.; Todoerti, K.; Agnelli, L.; Missale, G.; Andreoli, R.; et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: A new attractive target. *Blood* **2016**, *128*, 667–679. [CrossRef]

393. Galicia-Vázquez, G.; Smith, S.; Aloyz, R. Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. *Blood Cancer J.* **2018**, *8*, 13. [CrossRef]

394. Le, A.; Lane, A.N.; Hamaker, M.; Bose, S.; Gouw, A.; Barbi, J.; Tsukamoto, T.; Rojas, C.J.; Slusher, B.S.; Zhang, H.; et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. *Cell Metab.* **2012**, *15*, 110–121. [CrossRef]

395. Anastasiou, D. Tumour microenvironment factors shaping the cancer metabolism landscape. *Br. J. Cancer* **2017**, *116*, 277–286. [CrossRef] [PubMed]

396. Liu, Y.; Zhou, X.; Wang, X. Targeting the tumor microenvironment in B-cell lymphoma: Challenges and opportunities. *J. Hematol. Oncol.* **2021**, *14*, 125. [CrossRef] [PubMed]

397. Vangapandu, H.V.; Ayres, M.L.; Bristow, C.A.; Wierda, W.G.; Keating, M.J.; Balakrishnan, K.; Stellrecht, C.M.; Gandhi, V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. *Neoplasia* **2017**, *19*, 762–771. [CrossRef] [PubMed]

398. Yosifov, D.Y.; Idler, I.; Bhattacharya, N.; Reichenzeller, M.; Close, V.; Ezerina, D.; Scheffold, A.; Jebaraj, B.M.C.; Kugler, S.; Bloehdorn, J.; et al. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. *Leukemia* **2020**, *34*, 115–127. [CrossRef] [PubMed]

399. Zhang, W.; Trachootham, D.; Liu, J.; Chen, G.; Pelicano, H.; Garcia-Prieto, C.; Lu, W.; Burger, J.A.; Croce, C.M.; Plunkett, W.; et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. *Nat. Cell Biol.* **2012**, *14*, 276–286. [CrossRef]

400. Chen, Z.; Simon-Molas, H.; Cretenet, G.; Valle-Argos, B.; Smith, L.D.; Forconi, F.; Schomakers, B.V.; van Weeghel, M.; Bryant, D.J.; van Bruggen, J.A.C.; et al. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. *Blood* **2022**, *140*, 630–643. [CrossRef]

401. Burt, R.; Dey, A.; Aref, S.; Aguiar, M.; Akarca, A.; Bailey, K.; Day, W.; Hooper, S.; Kirkwood, A.; Kirschner, K.; et al. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. *Blood* **2019**, *134*, 1415–1429. [CrossRef]

402. Marlein, C.R.; Piddock, R.E.; Mistry, J.J.; Zaitseva, L.; Hellmich, C.; Horton, R.H.; Zhou, Z.; Auger, M.J.; Bowles, K.M.; Rushworth, S.A. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. *Cancer Res.* **2019**, *79*, 2285–2297. [CrossRef]

403. Panaroni, C.; Fulzele, K.; Mori, T.; Siu, K.T.; Onyewadume, C.; Maebius, A.; Raje, N. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. *Blood* **2022**, *139*, 876–888. [CrossRef]

404. Pavlides, S.; Tsirigos, A.; Vera, I.; Flomenberg, N.; Frank, P.G.; Casimiro, M.C.; Wang, C.; Fortina, P.; Addya, S.; Pestell, R.G.; et al. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the “reverse Warburg effect”: A transcriptional informatics analysis with validation. *Cell Cycle* **2010**, *9*, 2201–2219. [CrossRef] [PubMed]

405. Sotgia, F.; Whitaker-Menezes, D.; Martinez-Outschoorn, U.E.; Flomenberg, N.; Birbe, R.C.; Witkiewicz, A.K.; Howell, A.; Philp, N.J.; Pestell, R.G.; Lisanti, M.P. Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the “reverse Warburg effect” in positive lymph node tissue. *Cell Cycle* **2012**, *11*, 1445–1454. [CrossRef] [PubMed]

406. Gooptu, M.; Whitaker-Menezes, D.; Sprandio, J.; Domingo-Vidal, M.; Lin, Z.; Uppal, G.; Gong, J.; Fratamico, R.; Leiby, B.; Dulau-Florea, A.; et al. Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma. *Semin. Oncol.* **2017**, *44*, 204–217. [PubMed]

407. Sakamoto, A.; Kunou, S.; Shimada, K.; Tsunoda, M.; Aoki, T.; Iriyama, C.; Tomita, A.; Nakamura, S.; Hayakawa, F.; Kiyoi, H. Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. *Cancer Sci.* **2019**, *110*, 269–278. [CrossRef] [PubMed]

408. Mikkilineni, L.; Whitaker-Menezes, D.; Domingo-Vidal, M.; Sprandio, J.; Avena, P.; Cotzia, P.; Dulau-Florea, A.; Gong, J.; Uppal, G.; Zhan, T.; et al. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. *Semin. Oncol.* **2017**, *44*, 218–225. [CrossRef] [PubMed]

409. Alfaifi, A.; Bahashwan, S.; Alsaadi, M.; Malhan, H.; Aqeel, A.; Al-Kahiry, W.; Almehdar, H.; Qadri, I. Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment. *Diagnostics* **2022**, *12*, 394. [CrossRef]

410. Liu, X.; Wang, L.; Jiang, W.; Lu, W.; Yang, J.; Yang, W. B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. *J. Cancer* **2018**, *9*, 1582–1591. [CrossRef]

411. Barberini, L.; Noto, A.; Fattuoni, C.; Satta, G.; Zucca, M.; Cabras, M.G.; Mura, E.; Cocco, P. The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study. *Molecules* **2019**, *24*, 2367. [CrossRef]

412. Puchades-Carrasco, L.; Lecumberri, R.; Martínez-López, J.; Lahuerta, J.J.; Mateos, M.V.; Prósper, F.; San-Miguel, J.F.; Pineda-Lucena, A. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. *Clin. Cancer Res.* **2013**, *19*, 4770–4779. [CrossRef]
413. Bai, Y.; Zhang, H.; Sun, X.; Sun, C.; Ren, L. Biomarker identification and pathway analysis by serum metabolomics of childhood acute lymphoblastic leukemia. *Clin. Chim. Acta* **2014**, *436*, 207–216. [CrossRef]

414. MacIntyre, D.A.; Jiménez, B.; Lewintre, E.J.; Martín, C.R.; Schäfer, H.; Ballesteros, C.G.; Mayans, J.R.; Spraul, M.; García-Conde, J.; Pineda-Lucena, A. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. *Leukemia* **2010**, *24*, 788–797. [CrossRef] [PubMed]

415. Monti, S.; Savage, K.J.; Kutok, J.L.; Feuerhake, F.; Kurtin, P.; Mihm, M.; Wu, B.; Pasqualucci, L.; Neuberg, D.; Aguiar, R.C.; et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood* **2005**, *105*, 1851–1861. [CrossRef] [PubMed]

416. Caro, P.; Kishan, A.U.; Norberg, E.; Stanley, I.A.; Chapuy, B.; Ficarro, S.B.; Polak, K.; Tondera, D.; Gounarides, J.; Yin, H.; et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. *Cancer Cell* **2012**, *22*, 547–560. [CrossRef] [PubMed]

417. Chen, L.; Monti, S.; Juszczynski, P.; Daley, J.; Chen, W.; Witzig, T.E.; Habermann, T.M.; Kutok, J.L.; Shipp, M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. *Blood* **2008**, *111*, 2230–2237. [CrossRef]

418. Chiche, J.; Reverso-Meinietti, J.; Mouchotte, A.; Rubio-Patiño, C.; Mhaidly, R.; Villa, E.; Bossowski, J.P.; Proics, E.; Grima-Reyes, M.; Paquet, A.; et al. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. *Cell Metab.* **2019**, *29*, 1243–1257.e10. [CrossRef]

419. Lemberg, K.M.; Gori, S.S.; Tsukamoto, T.; Rais, R.; Slusher, B.S. Clinical development of metabolic inhibitors for oncology. *J. Clin. Investig.* **2022**, *132*, e148550. [CrossRef]

420. Stine, Z.E.; Schug, Z.T.; Salvino, J.M.; Dang, C.V. Targeting cancer metabolism in the era of precision oncology. *Nat. Rev. Drug Discov.* **2022**, *21*, 141–162. [CrossRef]

421. Pi, M.; Kuang, H.; Yue, C.; Yang, Q.; Wu, A.; Li, Y.; Assaraf, Y.G.; Yang, D.H.; Wu, S. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. *Drug Resist. Updates* **2022**, *61*, 100822. [CrossRef]

422. Gdynia, G.; Robak, T.; Kopitz, J.; Heller, A.; Grekova, S.; Duglova, K.; Laukemper, G.; Heinzel-Gutenbrunner, M.; Gutenbrunner, C.; Roth, W.; et al. Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. *eBioMedicine* **2018**, *32*, 125–133. [CrossRef] [PubMed]

423. Guièze, R.; Liu, V.M.; Rosebrock, D.; Jourdain, A.A.; Hernández-Sánchez, M.; Martinez Zurita, A.; Sun, J.; Ten Hacken, E.; Baranowski, K.; Thompson, P.A.; et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. *Cancer Cell* **2019**, *36*, 369–384.e13. [CrossRef]

424. Bajpai, R.; Sharma, A.; Achreja, A.; Edgar, C.L.; Wei, C.; Siddiqa, A.A.; Gupta, V.A.; Matulis, S.M.; McBrayer, S.K.; Mittal, A.; et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. *Nat. Commun.* **2020**, *11*, 1228. [CrossRef]

425. Chukkapalli, V.; Gordon, L.I.; Venugopal, P.; Borgia, J.A.; Karmali, R. Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. *Oncotarget* **2018**, *9*, 21166–21181. [CrossRef] [PubMed]

426. Ravera, S.; Ghiotto, F.; Tenca, C.; Gugiatti, E.; Santamaria, S.; Ledda, B.; Ibatici, A.; Cutrona, G.; Mazzarello, A.N.; Bagnara, D.; et al. Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients. *Sci. Rep.* **2020**, *10*, 16519. [CrossRef]

427. Vangapandu, H.V.; Havranek, O.; Ayres, M.L.; Kaipparettu, B.A.; Balakrishnan, K.; Wierda, G.D.W.; Keating, M.J.; Eric Davis, R.; Stellrecht, C.M.; Gandhi, V.; et al. B-cell receptor signaling regulates metabolism in chronic lymphocytic leukemia. *Mol. Cancer Res.* **2017**, *15*, 1692–1703. [CrossRef]

428. Chowdhury, R.S.; Bouchard, E.D.J.; Saleh, R.; Nugent, Z.; Peltier, C.; Mejia, E.; Hou, S.; McFall, C.; Squires, M.; Hewitt, D.; et al. Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment. *Cancers* **2020**, *12*, 650. [CrossRef]

429. Lee, S.C.; Shestov, A.A.; Guo, L.; Zhang, Q.; Roman, J.C.; Liu, X.; Wang, H.Y.; Pickup, S.; Nath, K.; Lu, P.; et al. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells. *Mol. Cancer Res.* **2019**, *17*, 1365–1377. [CrossRef] [PubMed]

430. Yang, M. B cell lymphoma R-CHOPped by metabolic inhibitors. *Sci. Transl. Med.* **2019**, *11*, 117. [CrossRef]

431. Gu, J.J.; Singh, A.; Xue, K.; Mavis, C.; Barth, M.; Yanamadala, V.; Lenz, P.; Grau, M.; Lenz, G.; Czuczman, M.S.; et al. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. *Oncotarget* **2018**, *9*, 4020–4033. [CrossRef] [PubMed]

432. Curtis, N.J.; Mooney, L.; Hopcroft, L.; Michopoulos, F.; Whalley, N.; Zhong, H.; Murray, C.; Logie, A.; Revill, M.; Byth, K.F.; et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. *Oncotarget* **2017**, *8*, 69219–69236. [CrossRef] [PubMed]

433. Singh, A.R.; Gu, J.J.; Zhang, Q.; Torka, P.; Sundaram, S.; Mavis, C.; Hernandez-Ilizaliturri, F.J. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma. *Cancer Metab.* **2020**, *8*, 10. [CrossRef] [PubMed]

434. Jiang, D.; Mo, Q.; Sun, X.; Wang, X.; Dong, M.; Zhang, G.; Chen, F.; Zhao, Q. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20. *Cancer Sci.* **2021**, *112*, 3585–3597. [CrossRef] [PubMed]
435. Ricci, J.E.; Chiche, J. Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. *Front. Oncol.* **2018**, *8*, 556. [CrossRef] [PubMed]

436. Thompson, R.M.; Dytfeld, D.; Reyes, L.; Robinson, R.M.; Smith, B.; Manevich, Y.; Jakubowiak, A.; Komarnicki, M.; Przybylowicz-Chalecka, A.; Szczepaniak, T.; et al. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. *Oncotarget* **2017**, *8*, 35863. [CrossRef]

437. Sanchez, W.Y.; McGee, S.L.; Connor, T.; Mottram, B.; Wilkinson, A.; Whitehead, J.P.; Vuckovic, S.; Catley, L. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. *Br. J. Cancer* **2013**, *108*, 1624–1633. [CrossRef] [PubMed]

438. Böttcher, M.; Baur, R.; Stoll, A.; Mackensen, A.; Mougiakakos, D. Linking Immunoevasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas. *Front. Oncol.* **2020**, *10*, 594782. [CrossRef]

439. Beielstein, A.C.; Pallasch, C.P. Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy. *Int. J. Mol. Sci.* **2019**, *20*, 4158. [CrossRef] [PubMed]

440. Li, X.; Wenes, M.; Romero, P.; Huang, S.C.; Fendt, S.M.; Ho, P.C. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. *Nat. Rev. Clin. Oncol.* **2019**, *16*, 425–441. [CrossRef]

441. Xu, X.; Gnanaprakasam, J.N.R.; Sherman, J.; Wang, R. A Metabolism Toolbox for CAR T Therapy. *Front. Oncol.* **2019**, *9*, 322. [CrossRef] [PubMed]

442. Xia, X.; Zhou, W.; Guo, C.; Fu, Z.; Zhu, L.; Li, P.; Xu, Y.; Zheng, L.; Zhang, H.; Shan, C.; et al. Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion. *Front. Oncol.* **2018**, *8*, 632. [CrossRef]

443. Blombery, P. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. *Leuk. Lymphoma* **2020**, *61*, 257–262. [CrossRef]

444. Diepstraten, S.T.; Anderson, M.A.; Czabotar, P.E.; Lessene, G.; Strasser, A.; Kelly, G.L. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. *Nat. Rev. Cancer* **2022**, *22*, 45–64. [CrossRef]

445. Lipsky, A.; Lamanna, N. Managing toxicities of Bruton tyrosine kinase inhibitors. *Hematol. Am. Soc. Hematol. Educ. Program* **2020**, *2020*, 336–345. [CrossRef] [PubMed]

446. George, B.; Chowdhury, S.M.; Hart, A.; Sircar, A.; Singh, S.K.; Nath, U.K.; Mamgain, M.; Singhal, N.K.; Sehgal, L.; Jain, N. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. *Cancers* **2020**, *12*, 1328. [CrossRef] [PubMed]

447. Wright, S.C.E.; Vasilevski, N.; Serra, V.; Rodon, J.; Eichhorn, P.J.A. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. *Cancers* **2021**, *13*, 1538. [CrossRef] [PubMed]

448. Yan, W.; Liu, Z.; Liu, J.; Xia, Y.; Hu, K.; Yu, J. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. *Biomed. Res. Int.* **2020**, *2020*, 4241864. [CrossRef] [PubMed]

449. Edeline, J.; Houot, R.; Marabelle, A.; Alcantara, M. CAR-T cells and BiTEs in solid tumors: Challenges and perspectives. *J. Hematol. Oncol.* **2021**, *14*, 65. [CrossRef]

450. Choi, B.D.; Yu, X.; Castano, A.P.; Bouffard, A.A.; Schmidts, A.; Larson, R.C.; Bailey, S.R.; Boroughs, A.C.; Frigault, M.J.; Leick, M.B.; et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. *Nat. Biotechnol.* **2019**, *37*, 1049–1058. [CrossRef]

451. Yin, Y.; Rodriguez, J.L.; Li, N.; Thokala, R.; Nasrallah, M.P.; Hu, L.; Zhang, L.; Zhang, J.V.; Logun, M.T.; Kainth, D.; et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. *Mol. Ther.* **2022**, *30*, 2537–2553. [CrossRef] [PubMed]

452. Ben-Shmuel, A.; Biber, G.; Barda-Saad, M. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? *Front. Immunol.* **2020**, *11*, 275. [CrossRef]

453. Xie, G.; Dong, H.; Liang, Y.; Ham, J.D.; Rizwan, R.; Chen, J. CAR-NK cells: A promising cellular immunotherapy for cancer. *eBioMedicine* **2020**, *59*, 102975. [CrossRef]

454. Islam, R.; Pupovac, A.; Evtimov, V.; Boyd, N.; Shu, R.; Boyd, R.; Trounson, A. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. *Cells* **2021**, *10*, 1058. [CrossRef] [PubMed]

455. Berenson, J.R.; Martinez, D.; Safaie, T.; Silagan, N.; To, J.; Spektor, T.M.; Forouzan, E.; Swift, R.; Eades, B.; Eshaghian, S.; et al. Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma. *Blood* **2021**, *138*, 2727. [CrossRef]

456. Italiano, A.; Soria, J.C.; Toulmonde, M.; Michot, J.M.; Lucchesi, C.; Varga, A.; Coindre, J.M.; Blakemore, S.J.; Clawson, A.; Suttle, B.; et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study. *Lancet Oncol.* **2018**, *19*, 649–659. [CrossRef] [PubMed]

457. Sarkozy, C.; Morschhauser, F.; Dubois, S.; Molina, T.; Michot, J.M.; Cullières-Dartigues, P.; Suttle, B.; Karlin, L.; Le Gouill, S.; Picquenot, J.M.; et al. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. *Clin. Cancer Res.* **2020**, *26*, 3145–3153. [CrossRef] [PubMed]

458. Morschhauser, F.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Batlevi, C.L.; Campbell, P.; Ribrag, V.; Damaj, G.L.; et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol.* **2020**, *21*, 1433–1442. [CrossRef]
459. Major, A.; Kline, J.; Karrison, T.G.; Fishkin, P.A.S.; Kimball, A.S.; Petrich, A.M.; Nattam, S.; Rao, K.; Sleckman, B.G.; Cohen, K.; et al. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. *Haematologica* **2022**, *107*, 1608–1618. [CrossRef]

460. Tan, F.H.; Putoczki, T.L.; Stylli, S.S.; Luwor, R.B. Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies. *Onco Targets Ther.* **2019**, *12*, 635–645. [CrossRef]

461. Cortes, J.E.; Kim, D.W.; Pinilla-Ibarz, J.; le Coutre, P.D.; Paquette, R.; Chuah, C.; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial. *Blood* **2018**, *132*, 393–404. [CrossRef]

462. Martinelli, G.; Papayannidis, C.; Piciocchi, A.; Robustelli, V.; Soverini, S.; Terragna, C.; Marconi, G.; Lemoli, R.M.; Guolo, F.; Fornaro, A.; et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Adv.* **2022**, *6*, 1742–1753. [CrossRef]

463. Ribera, J.M.; García-Calduch, O.; Ribera, J.; Montesinos, P.; Cano-Ferri, I.; Martínez, P.; Esteve, J.; Esteban, D.; García-Fortes, M.; Alonso, N.; et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood Adv.* **2022**, *6*, 5395–5402. [CrossRef]

464. Short, N.J.; Kantarjian, H.M.; Konopleva, M.; Jain, N.; Huang, X.; Ravandi, F.; Wierda, W.G.; Borthakur, G.; Sasaki, K.; Issa, G.C.; et al. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. *J. Clin. Oncol.* **2021**, *39*, 7001. [CrossRef]

465. Peterson, T.J.; Orozco, J.; Buege, M. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. *Ann. Pharmacother.* **2020**, *54*, 577–582. [CrossRef] [PubMed]

466. Sarnik, J.; Popławski, T.; Tokarz, P. BET Proteins as Attractive Targets for Cancer Therapeutics. *Int. J. Mol. Sci.* **2021**, *22*, 11102. [CrossRef]

467. Burgoyne, A.M.; Vann, K.R.; Joshi, S.; Morales, G.A.; Vega, F.M.; Singh, A.; Pal, D.; Merati, A.B.; Kutateladze, T.G.; Durden, D.L. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. *Cell Discov.* **2020**, *6*, 49. [CrossRef] [PubMed]

468. Smith, A.L.; Eiken, A.P.; Skupa, S.A.; Moore, D.Y.; Umeta, L.T.; Smith, L.M.; Lyden, E.R.; D'Angelo, C.R.; Kallam, A.; Vose, J.M.; et al. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. *Int. J. Mol. Sci.* **2022**, *23*, 6712. [CrossRef] [PubMed]

469. Vann, K.R.; Pal, D.; Smith, A.L.; Sahar, N.E.; Krishnaiah, M.; El-Gamal, D.; Kutateladze, T.G. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. *Mol. Biomed.* **2022**, *3*, 2. [CrossRef]

470. Martinez-Outschoorn, U.E.; Peiris-Pagés, M.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer metabolism: A therapeutic perspective. *Nat. Rev. Clin. Oncol.* **2017**, *14*, 113. [CrossRef]